FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma
Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.
Company
Pharmaceutical intelligence for Jiangsu Hansoh Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.